Sarepta Therapeutics kondigt publicatie resultaten klinische studie Eteplirsen aan

Sarepta Therapeutics kondigt resultaten klinische studie Eteplirsen aan, kandidaat middel Duchenne Muscular Dystrophy http://t.co/UcXu8kw8Yi
— Piet Wollaert (@teampelle) August 8, 2013

CAMBRIDGE, MA -- (Marketwired) -- 08/08/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced the first peer-reviewed publication of the 48-week results from the Phase IIb clinical study of eteplirsen in the Annals of Neurology. Eteplirsen is an investigational medicine in development for the treatment of patients with Duchenne muscular dystrophy (DMD) who have a genotype amenable to skipping of exon 51.